Pfizer hired 600 employees in the months after its COVID-19 vaccine was authorized in the United States due to the “large increase” of reports of side effects linked to the vaccine, according to a document prepared by the company.
Pfizer has “taken a multiple actions to help alleviate the large increase of adverse event reports,” according to the document. “This includes significant technology enhancements, and process and workflow solutions, as well as increasing the number of data entry and case processing colleagues.”
At the time when the document—from the first quarter of 2021—was sent to the U.S. Food and Drug Administration (FDA), Pfizer had onboarded about 600 extra full-time workers to deal with the jump.
“More are joining each month with an expected total of more than 1,800 additional resources by the end of June 2021,” Pfizer said.
Merck’s newly FDA-approved COVID-19 antiviral drug, molnupiravir, may pose severe health consequences despite being purchased in bulk by the Biden administration prior to its approval.
According to the New York Times, the purported wonder drug may have “the potential to cause mutations in human DNA.”
Of particular concern are pregnant women, because researchers say that “the drug could affect a fetus’s dividing cells, theoretically causing birth defects.” One researcher said “there is no circumstance” in which he would advise a pregnant woman to take the drug, as a result.
Buried in the middle of the New York Times article, the author explains that researchers are concerned the drug could “cause errors” in a patient’s DNA, or the DNA of an unborn child.
According to a team of researchers in North Carolina, those “errors” could cause DNA mutations that may “contribute to the development of cancer, or cause birth defects either in a developing fetus or through incorporation into sperm precursor cells.”
A Fact Sheet for Vaccine Providers published on the Food and Drug Administration (FDA) website admits that “Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 Vaccine.” The Fact Sheet was issued in response to the FDA granting an emergency use authorization for the Pfizer vaccine for people aged 12 and older. The Fact Sheet also notes that the Pfizer vaccine carries risk of the heart conditions myocarditis and pericarditis in addition to numerous other ailments that have been reported in clinical trials, and that “immunocompromised persons…may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.” Recent former FDA commissioner Scott Gottlieb (pictured above) is now on the board of directors of Pfizer. A contingent of recent Pfizer workers who serve on an FDA advisory committee are trying to get the FDA to authorize a Pfizer vaccine for children aged 5 to 11.
The potentially serious heart disorders of pericarditis, inflammation of the heart’s surrounding membrane; and myocarditis, inflammation of the heart muscle, are happening after Covid-19 vaccination substantially more often than previously reported.
That’s according to new research led by Dr. George Diaz, Section of Infectious Diseases, Providence Regional Medical Center Everett, Everett, Washington; published in the Journal of the American Medical Association (JAMA).
Diaz and his co-authors reviewed electronic medical hospital records of more than 2 million people who received at least one Covid-19 vaccination. They found 37 cases of vaccine-related pericarditis and 20 cases of vaccine-related myocarditis. That’s still “rare,” but far more than what was expected had Centers for Disease Control’s (CDC’s) numbers from the Vaccine Adverse Event Reporting System (VAERS) been accurate.
According to CDC, myocarditis was reported to the VAERSS at a rate of about 4.8 cases per million, or less than 1/2 per 100,000 (.48 per 100,000). The disorder was reportedly lumped in together with pericarditis in the VAERS reporting analyzed by CDC.
But the new analysis unearthed a rate of 1.8 per 100,000 people for pericarditis and 1 in 100,000 for myocarditis. That’s a combined rate that’s more five times higher than thought: 2.8 people per 100,000 rather than 1/2 per 100,000.
The information seems to confirm what scientists have long said has long been well-established: there is a significant underreporting of adverse event reports to the federal VAERS system. Therefore, each report of an illness is presumed to be more prevalent than what’s documented through VAERS.